伊立替康联合多西他赛治疗一线化疗方案失败的老年晚期胃癌患者的临床效果  

Clinical efficacy of irinotecan combined with docetaxel for elderly patients with advanced gastric cancer who have experienced disease progress after first-line chemotherapy

作　　者：罗湘[1] 彭济勇 鲁志兵[1] 蔡凡 

机构地区：[1]江西省萍乡市人民医院肿瘤科,萍乡市337000

出　　处：《广西医学》2017年第12期1830-1833,共4页Guangxi Medical Journal

摘　　要：目的观察伊立替康联合多西他赛治疗一线化疗方案失败的老年晚期胃癌患者的疗效和安全性。方法选取老年晚期胃癌患者28例,均为一线化疗方案治疗失败。患者采用周方案伊立替康联合多西他赛治疗,2个化疗周期完成后评价疗效。结果 28例患者均可评价疗效,客观有效率为39.3%,疾病控制率为64.3%,中位无进展生存期、总生存期分别为4.2个月、8.2个月。不良反应主要为厌食、乏力、腹泻和骨髓抑制,以Ⅰ~Ⅱ度为主。结论老年晚期胃癌患者一线方案化疗失败后,采用伊立替康联合多西他赛周方案二线治疗有效且安全。Objective To investigated the efficacy and safety of irinotecan combined with docetaxel for elderly patients with advanced gastric cancer who have experienced disease progression after first-line chemotherapy. Methods The clinical data of 28 elderly patients with advanced gastric cancer,who experienced disease progression after first-line chemotherapy,were retrospectively analyzed. The patients received a weekly therapeutic plan of irinotecan combined with docetaxel,and the evaluation on the efficacy was performed after two sessions of chemotherapy. Results The efficacy on the 28 patients were evaluated. The objective response rate,disease control rate,median progression-free survival and overall survival were 39. 3%,64. 3%,4. 2 months and 8. 2 months,respectively. The common adverse reactions were anorexia,fatigue,diarrhea and myelosuppression,mainly of Ⅰ to Ⅱ degree. Conclusion Weekly irinotecan combined with docetaxel as second-line chemotherapy regimen is effective and safe for the treatment of elderly patients with advanced gastric cancer who have experienced disease progression after first-line chemotherapy.

关 键 词：胃癌 晚期 二线方案 化疗 伊立替康 多西他赛 老年人 

分 类 号：R735.2[医药卫生—肿瘤]